Page 54 - Read Online
P. 54

Spieler et al. Hepatoma Res 2019;5:4  I  http://dx.doi.org/10.20517/2394-5079.2018.77                                          Page 11 of 13


               Availability of data and materials
               Not applicable.

               Financial support and sponsorship
               None.

               Conflicts of interest
               Dr. Eric A. Mellon received traveling support from ViewRay; Dr. Lorraine Portelance is a member of BTG
               compatibles Ready90 registry advisory board and dosimetry advisory board. She has received speaker
               support from BTG for talk on SABR; Dr. Lorraine Portelance received honorarium as a moderator in a
               ViewRay symposium.

               Ethical approval and consent to participate
               Not applicable.

               Consent for publication
               Not applicable.


               Copyright
               © The Author(s) 2019.



               REFERENCES
               1.   WHO. WHO mortality database. Available from: http://www.who.int/healthinfo/mortality_data/en/. [Last accessed on 7 Jan 2019]
               2.   White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000
                   through 2012. Gastroenterology 2017;152:812-20.
               3.   Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.
                   Hepatology 2011;53:1020-2.
               4.   Singal AG, Yopp AC, Gupta S, Skinner CS, Halm EA, et al. Failure rates in the hepatocellular carcinoma surveillance process. Cancer
                   Prev Res (Phila) 2012;5:1124-30.
               5.   Trevisani F, De Notariis S, Rapaccini G, Farinati F, Benvegnù L, et al. Semiannual and annual surveillance of cirrhotic patients for
                   hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-44.
               6.   Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24.
               7.   Jarnagin W, Chapman WC, Curley S, D’Angelica M, Rosen C, et al. Surgical treatment of hepatocellular carcinoma: expert consensus
                   statement. HPB (Oxford) 2010;12:302-10.
               8.   El-Serag HB. Epidemiology of hepatocellular carcinoma in USA. Hepatol Res 2007;37:S88-94.
               9.   Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular
                   carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.
               10.  Benson AB 3rd, D’Angelica MI, Abbott DE, Abrams TA, Alberts SR, et al. NCCN guidelines insights: hepatobiliary cancers, version
                   1.2017. J Natl Compr Canc Netw 2017;15:563-73.
               11.  Kothary N, Dieterich S, Louie JD, Chang DT, Hofmann LV, et al. Percutaneous implantation of fiducial markers for imaging-guided
                   radiation therapy. AJR Am J Roentgenol 2009;192:1090-6.
               12.  Kishan AU, Cao M, Mikaeilian AG, Low DA, Kupelian PA, et al. Dosimetric feasibility of magnetic resonance imaging-guided tri-
                   cobalt 60 preoperative intensity modulated radiation therapy for soft tissue sarcomas of the extremity. Pract Radiat Oncol 2015;5:350-6.
               13.  Eccles CL, Dawson LA, Moseley JL, Brock KK. Interfraction liver shape variability and impact on GTV position during liver
                   stereotactic radiotherapy using abdominal compression. Int J Radiat Oncol Biol Phys 2011;80:938-46.
               14.  Ten Haken RK, Balter JM, Marsh LH, Robertson JM, Lawrence TS. Potential benefits of eliminating planning target volume
                   expansions for patient breathing in the treatment of liver tumors. Int J Radiat Oncol Biol Phys 1997;38:613-7.
               15.  Wagman R, Yorke E, Ford E, Giraud P, Mageras G, et al. Respiratory gating for liver tumors: use in dose escalation. Int J Radiat Oncol
                   Biol Phys 2003;55:659-68.
               16.  Dawson LA, Brock KK, Kazanjian S, Fitch D, McGinn CJ, et al. The reproducibility of organ position using active breathing control
                   (ABC) during liver radiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1410-21.
               17.  Law AL, Ng WT, Lee MC, Chan AT, Fung KH, et al. Treatment of primary liver cancer using highly-conformal radiotherapy with kV-
                   image guidance and respiratory control. Radiother Oncol 2012;102:56-61.
               18.  Winter JD, Wong R, Swaminath A, Chow T. Accuracy of robotic radiosurgical liver treatment throughout the respiratory cycle. Int J
                   Radiat Oncol Biol Phys 2015;93:916-24.
               19.  Wojcieszynski AP, Rosenberg SA, Brower JV, Hullett CR, Geurts MW, et al. Gadoxetate for direct tumor therapy and tracking with
                   real-time MRI-guided stereotactic body radiation therapy of the liver. Radiother Oncol 2016;118:416-8.
   49   50   51   52   53   54   55   56   57   58   59